Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1
Emu B, Fessel W, Schrader S, Kumar P, Richmond G, Win S, Weinheimer S, Marsolais C, Lewis S. Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1. Open Forum Infectious Diseases 2017, 4: s38-s39. PMCID: PMC5632088, DOI: 10.1093/ofid/ofx162.093.Peer-Reviewed Original ResearchResistant HIV-1Week 24Long-term safetyWeek 48HIV-1Copies/MDR patientsLoading doseDurable efficacyMulti-drug resistant HIV-1Median viral load reductionMDR HIV-1Open-label studyTreatment-experienced patientsPhase 3 studyIntravenous loading doseUnexpected safety concernsValuable treatment optionWeeks of treatmentViral load reductionHumanized monoclonal antibodyARV classesBackground regimenCD4 depletionVirologic suppression